Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.



655305394

KIFI

Idaho Falls

Bonneville County

Idaho

United States

Biogen discontinues Alzheimer’s medication Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential blockbuster but it stumbled after its launch a few years ago. The drugmaker also

Ad Fontes Media

All Sides

Media Bias/Fact Check

Associated Press News

Independent Media

Biogen will stop selling its controversial Alzheimer's drug Aduhelm

Biogen will give up ownership and halt sales of Aduhuelm, an Alzheimer's disease drug that met skepticism and scrutiny following its 2021 approval.

USA Today

Gannett

Biogen ditches Aduhelm, an Alzheimer's drug that was approved amid controversy

Biogen will stop selling its Alzheimer’s treatment Aduhelm

abc News

The Walt Disney Company

The FDA, the American regulatory body, had granted accelerated approval to Aduhelm in the USA in June 2021. A controversial drug that was announced as a pioneer in the treatment of cognitive decline associated with Alzheimer's disease, was withdrawn from the market. The announcement was made by the manufacturer itself, the biotechnology company Biogen.
Biogen said it would suspend manufacturing, distribution, and sales of the drug Aduhelm to ded…

A FDA, órgão regulatório americano, havia concedido aprovação acelerada ao Aduhelm nos EUA em junho de 2021 Um controverso medicamento que foi anunciado como pioneiro no tratamento do declínio cognitivo associado à doença de Alzheimer, foi retirado do mercado. O anúncio foi feito pelo próprio fabricante, a  empresa de biotecnologia Biogen.
A Biogen disse que suspenderia a fabricação, distribuição e vendas do medicamento Aduhelm para dedicar mais…

Alzheimer: Biogen abandona remédio polêmico, o Aduhelm, após 17 anos de investimentos; entenda

Globo

Roberto Irineu Marinho

Brazil

Alzheimer's: Biogen abandons controversial drug, Aduhelm, after 17 years of investments; understand

By Carma Hassan, CNN (CNN) — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company said in a statement on Wednesday. “As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient needs. We plan to further adva…

News-Press & Gazette Company

By Carma Hassan and Jen Christensen, CNN (CNN) — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company said in a statement Wednesday. “As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient needs. We pla…

KRDO

Colorado Springs

El Paso County

Colorado

Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."

CNBC

Roberts family

Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments

By TOM MURPHY
AP Health Writer Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple of years ago. The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration, and it will stop sales of Aduhelm. Patients taking doses of the treatment available through the commercial market can c…

KVIA

Panama City

Bay County

Florida

Biogen plans to shut down its controversial Alzheimer's drug Aduhelm

Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval. Biogen said on Wednesday it would discontinue developing and commercializing Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use and terminate the ENVISION clinical study.  Related: Slow Market Penetration For Biogen’s Another Alzheimer’s Drug: UB…

Benzinga

New York

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines - Biogen (NASDAQ:BIIB)

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday […]

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics